Chondrosarcoma Clinical Trials 2024

Chondrosarcoma Clinical Trials 2024

Chondrosarcoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in chondrosarcoma clinical trials today.

Chondrosarcoma Clinical Trials

Here are the 6 most popular medical studies for chondrosarcoma

Popular filter options for chondrosarcoma trials

Soft Tissue Sarcoma Clinical Trials

View 8 Soft Tissue Sarcoma medical studies.

STS Clinical Trials

View 8 STS medical studies.

Chondrosarcoma Clinical Trials With No Placebo

View 22 chondrosarcoma medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to chondrosarcoma

What are the top hospitals conducting chondrosarcoma research?

In the realm of clinical trials targeting chondrosarcoma, several top hospitals have emerged as beacons of hope for patients. Among them is Memorial Sloan Kettering Cancer Center in New York, which currently leads the pack with six active trials focused on this rare form of bone cancer. Having recorded its first chondrosarcoma trial in 2018, Memorial Sloan Kettering's dedication to finding effective treatments is evident. MD Anderson Cancer Center in Houston joins the ranks with five ongoing chondrosarcoma trials and a history that dates back to their inaugural study in 2006. Not far behind is the Sarcoma Oncology Center located amidst sunny Santa Monica, California. This center boasts four active clinical trials for chondrosarcoma and began its journey towards combating this condition in 2007.

Houston's M D Anderson Cancer Center remains steadfastly committed to fighting against this malignancy as well, seeking innovative solutions through three current chondrosarcoma trials since recording their first investigation also around 2007.Boston's Massachusetts General Hospital rounds out this list by offering three active clinical studies regarding chondrosarcoma while having embarked on their exploration into this cancer type as early as1999.

Chondrosarcoma presents unique challenges due to its rarity and complexity; however, these leading hospitals' unwavering commitment showcases the progress being made in understanding and treating this disease. Collaborative efforts across institutions provide invaluable opportunities for patients affected by chondrosarcoma, inching closer towards improved outcomes and ultimately a brighter future for those diagnosed with this challenging condition

Which are the best cities for chondrosarcoma clinical trials?

When it comes to chondrosarcoma clinical trials, several cities emerge as prime hubs for research and development. Houston, Texas leads the pack with 13 active trials investigating treatments such as AG-120, INBRX-109, and Proton Beam Therapy. Following closely behind are Los Angeles, California and New york, New York, both with 11 ongoing studies focusing on therapies like Doxorubicin, LY3410738, and INBRX-109. Chicago, Illinois also shows promise with 10 active trials examining options such as Doxorubicin and LY3410738. Lastly, Boston,Masachusetts offers hope with 8 ongoing studies exploring treatments like LY3410738and AG-120.In these cities across the United States,chondrosarcoma patients have access to cutting-edge clinical trials that may pave the way for improved treatment outcomes.It's important to consult medical professionals for specific recommendations tailored to individual cases.

Which are the top treatments for chondrosarcoma being explored in clinical trials?

Exciting progress is being made in clinical trials for chondrosarcoma, with several top treatments showing promise. AG-120 has emerged as a frontrunner, currently undergoing two active trials and contributing to the total of two all-time chondrosarcoma trials since its listing in 2014. Another contender capturing attention is INBRX-109, involved in two ongoing trials and adding to the tally of two all-time chondrosarcoma studies since 2018. Equally significant is seclidemstat, also participating in two current trials and entering the field in 2018. Lastly, an intriguing newcomer on the scene is CD30 biAb-AATC—a cutting-edge treatment that recently commenced one active trial after its first listing just this year (2022). These advancements mark important strides towards improved therapies for individuals battling chondrosarcoma.

What are the most recent clinical trials for chondrosarcoma?

Recent clinical trials offer hope and potential advancements in the treatment of chondrosarcoma, a rare form of bone cancer. One trial focuses on an experimental therapy called anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC). This innovative approach combines targeted antibodies with activated immune cells to attack cancer cells specifically. Another trial investigates the efficacy of YH001 combined with Envafolimab, aiming to determine the recommended dose for treating chondrosarcoma subtype 1. Additionally, Seclidemstat is being evaluated as a potential therapeutic option for this aggressive tumor type. These studies provide valuable insights into new treatment avenues that may improve outcomes for individuals battling chondrosarcoma.

What chondrosarcoma clinical trials were recently completed?

A recent milestone has been reached in the field of chondrosarcoma research, with the completion of a clinical trial investigating FT-2102. Conducted by Forma Therapeutics, Inc., this trial concluded in November 2018. This significant endeavor contributes valuable insights to our understanding and treatment approaches for chondrosarcoma, highlighting the ongoing efforts to improve outcomes for patients affected by this challenging condition.